Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Otolaryngol Head Neck Surg. 1999 Aug;125(8):864-8.

Autologous and heterologous blood transfusion in head and neck cancer surgery.

Author information

  • 1Department of Surgery, Stanford University Medical Center, Calif 94305-5328, USA.

Abstract

OBJECTIVE:

To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion.

DESIGN:

Retrospective medical record review.

SETTING:

Tertiary care hospital.

PATIENTS:

One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994.

MAIN OUTCOME MEASURES:

We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used.

RESULTS:

Heterologous blood recipients had a 59% recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33% and 35%, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P<.001); receipt of heterologous blood (P = .04); positive margin (P = .04); and nodal disease (P = .04). The receipt of heterologous blood was associated with a 40% increased risk for recurrence.

CONCLUSION:

Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.

PMID:
10448732
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center